TB Alliance announced that its compound TBA-354 has started Phase I clinical trials. This announcement is particularly exciting given that TBA-354 is the first TB drug to enter Phase I trials since 2009. TBA-354 is a next generation compound in the nitroimidazole class, which also includes pretomanid (PA-824). This class of drugs is known to be effective against drug-sensitive and drug-resistant tuberculosis and currently pretomanid is being tested in several clinical trials.
To read the official press release from TB Alliance, click here.
Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis